News

Unlike approved antidepressant drugs which have warnings on their labels stating they may increase the suicide risk, NRX-101 demonstrates meaningful reductions in suicidality.

Patients with AATD had increased cardiovascular risk compared to non-AATD COPD and healthy controls, with results suggesting physiological tests may assess risk more accurately.

The FDA approved eculizumab-aeeb (Bkemv) as an interchangeable biosimilar to eculizumab (Soliris) for treating PNH and aHUS, marking the agency’s 53rd biosimilar approval.

Deepak Sambhara, MD, describes the influence of baseline central retinal thickness on visual outcomes in a post-hoc analysis of the PHOTON study.

Bonder explains key therapeutic targets in primary biliary cholangitis and why combination obeticholic acid and bezafibrate may be a promising option.

Relacorilant achieves primary endpoint in phase 3 GRACE trial among patients with hypercortisolism and hyperglycemia, hypertension or both, with sNDA expected in Q3 2024.

Phase 2b study results show that investigational plozasiran significantly reduced triglyceride-rich lipoproteins in patients with mixed hyperlipidemia.

Ji Hyun “CJ” Chun, MPAS, PA-C, BC-ADM, explains how the adoption of 5 new diabetes subtypes may foster precision care.

A new study found a greater PCSK9 is associated with a greater cutaneous melanoma risk.

Jonathan Barratt, MD, discusses a matching-adjusted indirect comparison of sparsentan and irbesartan against standard of care plus optimized RASI.

An analysis of more than 800 IgAN patients treated from 2002-2021 provides an overview of factors associated with anemia as well as its impact on prognosis.

Fadi Fakhouri, MD, PhD, discusses the 1-year results of the NOBLE trial examining use of pegcetacoplan in patients with post-transplant C3G or IC-MPGN.

A phase 2b dose-finding study suggests use of clazakizumab was associated with a reduction in hs-CRP among patients undergoing maintenance dialysis.

Jonathan Barratt, MD, discusses the 52-week data from the phase 1/2 trial of zigakibart, which was presented at the 61st European Renal Association Congress.

A Q&A with David Kavanagh, MBChB, PhD, on the results of the APPEAR-C3G trial and implications for care moving forward.

The phase 2 NOBLE trial shows pegcetacoplan reduces disease activity in post-transplant C3G and IC-MPGN, with benefits persisting through the 40-week double-blind period.

In the APPEAR-C3G trial, iptacopan reduced proteinuria by 35.1% in patients with C3 glomerulopathy, with Novartis planning regulatory submissions for C3G before the end of 2024.

Helen Colhoun, MD, discusses the results of a SELECT analysis she presented at the 61st European Renal Association Congress.

Semaglutide 2.4 mg reduces kidney events in SELECT participants, showing renoprotective effects in addition to cardiovascular benefits.

Circulating antinephrin autoantibodies identified as reliable biomarkers for MCD and primary FSGS, enhancing diagnostic precision and monitoring of nephrotic syndromes.

Data from ERA 24 builds on previous research examining the effect of SGLT2 inhibitors on hemoglobin levels among patients with chronic kidney disease.

Hear from Katharina Mayer, MD, and Georg Böhmig, MD, on the results of the phase 2 trial of felzartamab in patients with antibody-mediated rejection following kidney transplantation.

Atrasentan significantly reduces proteinuria in patients with IgA nephropathy, showing a 36.1% reduction compared to placebo at 36 weeks.

Hosts break down the FLOW trial, take a deep dive into secondary findings, and provide insight into how this alters the perception of the role for semaglutide in management of CKD in type 2 diabetes.

Study finds roxadustat effectively treats anemia in both dialysis-dependent and non-dialysis-dependent CKD patients.

ORION-8 demonstrates the consistent long-term efficacy and tolerability of twice-yearly inclisiran over a mean cumulative exposure of 3.7 years.

Vlado Perkovic, MBBS, PhD, discusses the results of the FLOW trial and their implications for clinical practice at ERA 24.

New study finds SGLT2 inhibitors reduce proteinuria in IgA nephropathy, with greater initial eGFR dips predicting stronger treatment responses.